1. Home
  2. FUSEW vs SCNI Comparison

FUSEW vs SCNI Comparison

Compare FUSEW & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FUSEW
  • SCNI
  • Stock Information
  • Founded
  • FUSEW N/A
  • SCNI 2003
  • Country
  • FUSEW United States
  • SCNI Israel
  • Employees
  • FUSEW N/A
  • SCNI N/A
  • Industry
  • FUSEW EDP Services
  • SCNI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FUSEW Technology
  • SCNI Health Care
  • Exchange
  • FUSEW Nasdaq
  • SCNI Nasdaq
  • Market Cap
  • FUSEW 5.4M
  • SCNI 4.6M
  • IPO Year
  • FUSEW N/A
  • SCNI N/A
  • Fundamental
  • Price
  • FUSEW $0.14
  • SCNI $0.93
  • Analyst Decision
  • FUSEW
  • SCNI
  • Analyst Count
  • FUSEW 0
  • SCNI 0
  • Target Price
  • FUSEW N/A
  • SCNI N/A
  • AVG Volume (30 Days)
  • FUSEW N/A
  • SCNI 63.0K
  • Earning Date
  • FUSEW N/A
  • SCNI 11-24-2025
  • Dividend Yield
  • FUSEW N/A
  • SCNI N/A
  • EPS Growth
  • FUSEW N/A
  • SCNI N/A
  • EPS
  • FUSEW N/A
  • SCNI 0.26
  • Revenue
  • FUSEW N/A
  • SCNI $1,147,000.00
  • Revenue This Year
  • FUSEW N/A
  • SCNI N/A
  • Revenue Next Year
  • FUSEW N/A
  • SCNI N/A
  • P/E Ratio
  • FUSEW N/A
  • SCNI $3.65
  • Revenue Growth
  • FUSEW N/A
  • SCNI 303.87
  • 52 Week Low
  • FUSEW N/A
  • SCNI $0.89
  • 52 Week High
  • FUSEW N/A
  • SCNI $6.18
  • Technical
  • Relative Strength Index (RSI)
  • FUSEW N/A
  • SCNI 31.20
  • Support Level
  • FUSEW N/A
  • SCNI $0.89
  • Resistance Level
  • FUSEW N/A
  • SCNI $1.07
  • Average True Range (ATR)
  • FUSEW 0.00
  • SCNI 0.12
  • MACD
  • FUSEW 0.00
  • SCNI -0.02
  • Stochastic Oscillator
  • FUSEW 0.00
  • SCNI 12.52

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: